Cyclic Guanidinyl OX2R Agonists for Sleep and Obesity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sleep disorders and obesity lack effective, non-peptidic small-molecule agonists for the type-2 orexin receptor (OX2R) that can modulate sleep-wake control and body weight homeostasis.
Innovation Solution
Development of chemically distinct small-molecule OX2R agonists, represented by specific compound formulas (A) to (VIII), which are designed to interact with the OX2R, promoting wakefulness and anti-obesity effects by modulating orexin receptor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-peptidic small-molecule agonists for OX2R are developed, then therapeutic benefits for sleep disorders and obesity are achieved, but the complexity of molecule design and synthesis increases
Solution Approach 1:
The invention divides the complex OX2R binding interface into distinct structural components (aromatic ring systems, basic nitrogen atoms, specific substituent patterns) that can be independently optimized. Each compound class (I-VIII) represents a segmented approach to achieving the required molecular features for OX2R agonism without requiring complete peptide mimicry.
Solution Approach 2:
The invention systematically varies key molecular parameters including aromatic ring substitution patterns, alkyl chain lengths, heterocyclic ring types, and basic nitrogen configurations across eight different compound classes. This parameter optimization allows achievement of potent OX2R agonism through non-peptidic structures, resolving the contradiction between therapeutic effectiveness and design complexity.
2Adaptability or versatility
If chemically distinct classes of OX2R agonists are created, then versatility in treating sleep and metabolic disorders is improved, but the number of compounds to evaluate and develop increases
Solution Approach 1:
The invention creates eight chemically distinct compound classes (I-VIII) that all share the core functionality of OX2R agonism while exhibiting different chemical properties and pharmacokinetic profiles. This universal approach allows selection of the most suitable compound class for specific therapeutic indications, improving versatility without requiring evaluation of every possible molecule.
Solution Approach 2:
The invention uses representative compounds from each of the eight classes as prototypes that capture the essential pharmacological activity. Once a lead compound is identified in any class, structure-activity relationship studies can be conducted within that chemical series, reducing the need to evaluate all eight classes exhaustively and improving development efficiency.
Data Source
AI summary
Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.